Hemoptysis — Med2Date

📋 Key Information Summary

📋

Define hemoptysis clearly: expectoration of blood originating from the lower respiratory tract (below the glottis); always exclude pseudohemoptysis (upper GI, nasopharyngeal, or oropharyngeal sources) and hematemesis before initiating workup.
Quantify the volume: massive hemoptysis is defined as ≥200 mL in 24 hours (some sources use ≥500–600 mL/24h); mortality rises sharply above 1,000 mL/24h and is driven by asphyxiation rather than exsanguination.
Massive hemoptysis is a medical emergency: establish large-bore IV access, cross-match blood, position the patient bleeding-side-down, secure the airway (consider single-lumen ETT advanced to main bronchus of non-bleeding lung), and activate interventional radiology for bronchial artery embolization (BAE).
Bronchiectasis is the leading cause in Australia, particularly in the setting of chronic lung disease, post-infectious damage, and cystic fibrosis; tuberculosis and lung malignancy are the next most common aetiologies.
CT pulmonary angiography (CTPA) is the imaging modality of choice for suspected pulmonary embolism presenting with hemoptysis; contrast-enhanced CT of the thorax with arterial phase is preferred for identifying bronchial artery pathology and localising bleeding.
Fibreoptic bronchoscopy is indicated for localising the bleeding source when CT is non-diagnostic, in recurrent hemoptysis, and when malignancy is suspected; perform during active bleeding when feasible or within 24–48 hours of cessation.
Bronchial artery embolization (BAE) is the first-line treatment for massive and life-threatening hemoptysis, with immediate success rates of 70–90%; recurrence rates are 10–30% and are highest in aspergilloma and malignancy.
Surgical resection is reserved for BAE failure or specific anatomical lesions (e.g., aspergilloma, localised bronchiectasis, cavitary lung disease) and carries operative mortality of 7–18% in emergency settings.
Treat the underlying cause: antibiotics for pneumonia and bronchiectasis exacerbations, anti-tuberculosis therapy (ATT), oncological management for lung cancer, anticoagulation for PE, and immunosuppression for vasculitis.
Tranexamic acid (TXA) — 1 g IV stat in massive hemoptysis, followed by 1 g IV over 8 hours; consider 500 mg–1 g TDS PO for non-massive hemoptysis while investigating (PBS Authority Required for oral form).
Aboriginal and Torres Strait Islander Australians have disproportionately higher rates of bronchiectasis, tuberculosis, and rheumatic heart disease — all key causes of hemoptysis; remote access to bronchoscopy and embolization services remains a significant barrier.
Red flags for immediate escalation: hemodynamic instability, massive bleeding (>200 mL/24h), respiratory compromise, anticoagulant or antiplatelet use, and suspected pulmonary embolism — all warrant emergent resuscitation and specialist consultation.

Introduction & Australian Epidemiology

Hemoptysis — the expectoration of blood or blood-streaked sputum originating from the lower respiratory tract — is a presenting symptom that ranges from self-limited and benign to life-threatening. It accounts for approximately 10–15% of pulmonary outpatient referrals and 5–15% of respiratory-related hospital admissions in Australia. While the majority of cases are caused by acute bronchitis or mild lower respiratory tract infections, clinicians must maintain a high index of suspicion for serious underlying pathology including bronchiectasis, tuberculosis (TB), lung cancer, and pulmonary embolism (PE).

In Australia, bronchiectasis — both cystic fibrosis (CF)-related and non-CF-related — is the single most common cause of significant hemoptysis, accounting for 20–30% of cases in published Australian series. Lung cancer and TB together account for a further 20–40%, with the relative proportions varying by geography and population. In remote and regional Aboriginal and Torres Strait Islander communities, post-infectious bronchiectasis and TB remain disproportionately prevalent, with notification rates of TB in Indigenous Australians approximately 1.5 times those of non-Indigenous Australians.

Massive hemoptysis — typically defined as ≥200 mL in 24 hours — carries a mortality of 50–100% without intervention, with death occurring primarily from asphyxiation rather than haemorrhagic shock. The availability of bronchial artery embolization (BAE) at major tertiary centres (including Royal Prince Alfred Hospital Sydney, The Alfred Melbourne, Royal Brisbane and Women's Hospital, and Sir Charles Gairdner Hospital Perth) has reduced in-hospital mortality from massive hemoptysis to 7–18%.

⚠️

Asphyxiation, not exsanguination: In massive hemoptysis, the primary cause of death is airway obstruction by blood and clot. Prioritise airway protection and bleeding-side-down positioning before pursuing diagnosis.

Assessment & Quantification

Initial Clinical Assessment

The initial approach to the patient presenting with hemoptysis must address three sequential questions: (1) Is this truly hemoptysis from the lower respiratory tract? (2) How much blood is being lost and is the patient physiologically stable? (3) What is the likely source and underlying cause?

Pseudohemoptysis vs True Hemoptysis

Before pursuing a respiratory investigation pathway, clinicians must exclude pseudohemoptysis — the expectoration of blood originating from a non-pulmonary source. Common mimics include:

Hematemesis (upper GI bleeding): dark or coffee-ground vomitus, history of liver disease or peptic ulcer disease; the blood may be coughed up after vomiting (Boerhaave syndrome). Test: urea:creatinine ratio >100:1 favours GI origin.
Nasopharyngeal bleeding (epistaxis): anterior rhinoscopy or ENT assessment reveals posterior nasal drip source; common in patients on anticoagulation or with hereditary haemorrhagic telangiectasia (HHT).
Oropharyngeal bleeding: dental sources, tonsillar bleeding, or oral mucosal lesions; direct visualisation confirms the diagnosis.

ℹ️

Clinical differentiators: True hemoptysis is typically bright red, frothy (mixed with air), alkaline pH, and accompanied by cough. Hematemesis is darker, acidic, mixed with food particles, and preceded by nausea rather than cough. Sputum cytology for haemosiderin-laden macrophages supports a pulmonary origin.

Quantification: Massive vs Non-Massive

Quantification of hemoptysis volume is critical for triage and management decisions. While patient-reported volumes are often inaccurate (patients tend to overestimate), the following thresholds guide clinical urgency:

Non-Massive — Minor

<20 mL/24h

Blood-streaked sputum or small-volume hemoptysis. Stable vitals. Common in acute bronchitis, mild lower respiratory tract infections.

Setting: GP assessment; outpatient workup

Non-Massive — Moderate

20–200 mL/24h

Recurrent or moderately large volume hemoptysis without haemodynamic compromise. Requires inpatient investigation to exclude malignancy, bronchiectasis, TB, PE.

Setting: Hospital admission; urgent CT + bronchoscopy

Massive

≥200 mL/24h

Life-threatening. Risk of asphyxiation. May present with haemodynamic instability, respiratory distress, drop in haemoglobin >2 g/dL. Requires emergent resuscitation, airway management, and interventional radiology.

Setting: ICU/HDU; emergent BAE; surgical standby

🚨

Physiological instability overrides volume thresholds: Any hemoptysis — regardless of estimated volume — accompanied by haemodynamic compromise (systolic BP <90 mmHg, HR >110/min), respiratory distress (SpO₂ <92% on room air), or massive drop in haemoglobin should be managed as massive hemoptysis. Some patients die from asphyxiation with volumes as low as 100–150 mL if airway clearance is impaired.

Localisation of Bleeding

Bleeding-side-down positioning is the immediate management priority. Where history and imaging are non-diagnostic, lateralisation can be guided by:

Patient-reported side: unreliable alone (sensitivity ~50%), but should be documented.
Chest X-ray (CXR): focal infiltrate, mass, cavity, or ground-glass opacity may localise the bleeding side; normal CXR in up to 30% of hemoptysis cases.
CT thorax: highest yield for localisation (sensitivity 70–88%); arterial phase CT identifies hypertrophied bronchial arteries and active extravasation.
Bronchoscopy: definitive localisation in 73–93% when performed during active bleeding; yield drops to 50% if performed >48 hours after cessation.

Aetiology

The aetiology of hemoptysis is broad and varies with population, geography, and comorbidity. In Australian published series, the following causes predominate. Importantly, up to 20–30% of cases remain idiopathic after comprehensive investigation — these patients generally have an excellent prognosis (<5% rate of serious pathology at 5-year follow-up).

Cause	Approximate Frequency	Key Clinical Features	Australian Context
Bronchiectasis	20–30%	Chronic productive cough, recurrent infections, clubbing, coarse crackles	Leading cause in Australia; non-CF bronchiectasis very common in Indigenous Australians and CF populations
Tuberculosis	10–20%	Chronic cough, weight loss, night sweats, cavitary disease, immunosuppression	Higher rates in Indigenous communities, migrants from high-burden countries, immunocompromised; 1,300+ notifications/year nationally
Lung cancer	10–20%	Age >50, smoking history, weight loss, chest pain, new mass on imaging	Leading cause of cancer death in Australia (~9,000 deaths/year); hemoptysis in ~20–30% of lung cancer patients at some point
Acute bronchitis / LRTI	15–25%	Acute onset, self-limited, viral prodrome, mild blood-streaked sputum	Most common benign cause; usually managed in primary care
Pneumonia / lung abscess	5–10%	Fever, purulent sputum, focal consolidation, pleuritic chest pain	Community-acquired or aspiration-related; CA-MRSA necrotising pneumonia may present with severe hemoptysis
Aspergilloma / chronic pulmonary aspergillosis	5–10%	Pre-existing cavitary disease (TB, sarcoidosis), fungal ball on imaging	High risk of massive hemoptysis; recurrence after BAE is highest with aspergilloma
Pulmonary embolism	3–5%	Acute dyspnoea, pleuritic chest pain, tachycardia, DVT risk factors	Must exclude in any patient with hemoptysis + dyspnoea; CTPA is essential
Vasculitis (GPA, MPA, Goodpasture's)	1–3%	Hemoptysis + haematuria, raised inflammatory markers, positive ANCA/anti-GBM antibodies	Diffuse alveolar haemorrhage (DAH) is a rheumatological emergency requiring ICU admission and pulse IV methylprednisolone
Other (AVMs, coagulopathy, trauma, iatrogenic)	5–10%	HHT (Osler-Weber-Rendu), anticoagulant use, post-bronchoscopy, post-transplant	Consider iatrogenic in post-procedural patients; coagulopathy (DOAC, warfarin, thrombocytopenia) amplifies any source
Idiopathic	20–30%	Comprehensive investigation negative; usually minor or moderate volume	Excellent prognosis; recurrence risk <5% at 5 years; follow-up CXR recommended

Bronchiectasis

Bronchiectasis — permanent abnormal dilatation of bronchi — is the single most common cause of hemoptysis in Australian practice. Haemoptysis occurs in 46–69% of patients with bronchiectasis at some point in their disease course, and is the presenting symptom in 15–20%. The mechanism involves hypertrophied, fragile bronchial arteries (systemic pressure) eroding into the airway lumen. In Australia, non-CF bronchiectasis is particularly prevalent in Aboriginal and Torres Strait Islander communities, where childhood respiratory infections (including adenovirus, pertussis, and measles, prior to widespread vaccination) have contributed to post-infectious bronchiectasis.

Tuberculosis

TB remains a significant cause of hemoptysis in Australia, particularly in high-risk groups including Aboriginal and Torres Strait Islander Australians, migrants and refugees from high-burden countries (sub-Saharan Africa, South-East Asia, the Indian subcontinent), people experiencing homelessness, and immunocompromised individuals (HIV, biologics, transplant). Active pulmonary TB with cavitary disease is the most common TB-related cause of hemoptysis; however, old TB scars may serve as the substrate for aspergilloma formation, which itself carries a high risk of massive hemoptysis.

Lung Cancer

Lung cancer accounts for 10–20% of hemoptysis presentations and is the most common malignancy to cause hemoptysis. Squamous cell carcinoma is the histological subtype most likely to cause hemoptysis due to its central airway location and propensity for cavitation. Any patient aged ≥40 years with unexplained hemoptysis and a smoking history should be investigated urgently for lung cancer. In Australia, the National Lung Cancer Screening Program (commencing July 2025) will use low-dose CT to detect early-stage disease, though hemoptysis itself warrants prompt investigation beyond screening pathways.

Pulmonary Embolism

PE presents with hemoptysis in 3–5% of cases, typically as small-volume blood-streaked sputum associated with acute dyspnoea and pleuritic chest pain. The mechanism is pulmonary infarction. PE must be actively excluded in any patient presenting with hemoptysis and concurrent respiratory symptoms, particularly when DVT risk factors are present. Failure to diagnose PE in a patient with hemoptysis is a critical safety event — CTPA should not be omitted due to concerns about contrast in the setting of active bleeding.

Vasculitis and Diffuse Alveolar Haemorrhage (DAH)

DAH represents a rheumatological emergency. It is characterised by the triad of hemoptysis, new bilateral alveolar infiltrates on CXR/CT, and a drop in haemoglobin. The most common causes are granulomatosis with polyangiitis (GPA, formerly Wegener's), microscopic polyangiitis (MPA), and anti-glomerular basement membrane disease (anti-GBM, Goodpasture's syndrome). Renal involvement (rapidly progressive glomerulonephritis) coexists in up to 60% of cases. Urgent serological testing (ANCA, anti-GBM, complement) and nephrology/rheumatology referral are essential. First-line treatment is pulse IV methylprednisolone 500–1,000 mg daily for 3 days, followed by cyclophosphamide and/or rituximab.

Diagnostic Evaluation

The diagnostic workup for hemoptysis should be guided by the severity of bleeding, the clinical context, and the pre-test probability of serious underlying pathology. In all cases, the investigation pathway should proceed in parallel with resuscitation — do not delay management for diagnostic certainty in massive hemoptysis.

Laboratory Investigations

Essential Full blood count (FBC) Baseline haemoglobin, platelet count; serial monitoring in active bleeding (MBS item 65060)

Essential Coagulation profile (INR, APTT, fibrinogen) Exclude coagulopathy; critical in patients on anticoagulants or with suspected DIC

Essential Group & Hold / Crossmatch Mandatory for massive hemoptysis or haemodynamic instability; hold 2–4 units PRBCs

Essential Urea, creatinine, electrolytes Assess renal function; raised urea:creatinine ratio may suggest GI source; impaired renal function raises suspicion for vasculitis (MBS item 66500)

Available Sputum microscopy, culture, and sensitivity AFB smear and culture (3 specimens), bacterial culture, cytology — all sputum samples should be sent when hemoptysis is first identified

Available D-dimer Screening for PE in low-moderate risk patients; if elevated, proceed to CTPA (MBS item 69318)

Specialist ANCA (c-ANCA, p-ANCA), anti-GBM antibodies If vasculitis or DAH suspected; urgent referral to rheumatology/nephrology (MBS item 69344)

Specialist Aspergillus precipitins / IgE / galactomannan If aspergilloma or chronic pulmonary aspergillosis suspected

Imaging

Essential Chest X-ray (PA and lateral) First-line imaging; identifies mass, consolidation, cavity, effusion, or interstitial disease. Normal in up to 30% of hemoptysis cases — a normal CXR does not exclude serious pathology (MBS item 58500)

Essential Contrast-enhanced CT thorax The investigation of choice for hemoptysis of unknown cause. Arterial-phase acquisition identifies hypertrophied bronchial arteries and active extravasation. Sensitivity 70–88% for localising source. MBS item 56302 (with IV contrast). Should be performed urgently in moderate-volume hemoptysis or any haemodynamic compromise.

Essential CT pulmonary angiography (CTPA) Indicated when PE is suspected (dyspnoea, pleuritic pain, DVT risk factors, raised D-dimer). MBS item 69318. May be combined with arterial-phase CT in a single study.

Available High-resolution CT (HRCT) Best for bronchiectasis characterisation, interstitial lung disease, and chronic pulmonary aspergillosis. MBS item 56302.

Bronchoscopy

Fibreoptic (flexible) bronchoscopy is the gold standard for localising bleeding within the airways and obtaining tissue for histological and microbiological analysis. Rigid bronchoscopy offers superior suctioning and airway control in massive hemoptysis and is preferred in tertiary centres with the expertise to perform it.

Indication	Timing	Yield
Active hemoptysis (moderate–massive)	Emergent / within hours	73–93% localisation
CT non-diagnostic	Within 48 hours of cessation	Additional pathology found in 10–30%
Suspected endobronchial malignancy	Urgent (within 2 weeks per lung cancer pathways)	Diagnostic in 60–85% of central tumours
Suspected TB (sputum AFB negative)	Within 1–2 weeks	Bronchial washings AFB positive in additional 10–20%
Recurrent hemoptysis, no cause found	Elective, within 4 weeks	Identifies cause in 30–40% of initially negative cases

Bronchial Arteriography

Performed by interventional radiology, bronchial arteriography is both diagnostic and therapeutic (proceeding to embolization). It identifies hypertrophied and abnormal bronchial arteries, aberrant systemic arteries (from intercostal, subclavian, or internal mammary arteries), and active contrast extravasation. Available at all major Australian tertiary centres; patients in remote areas may require aeromedical retrieval (RFDS or equivalent).

Additional Investigations (as indicated)

Sweat test / CFTR genetics: if bronchiectasis in a young patient without known CF.
Immunoglobulins (IgG, IgA, IgM, IgG subclasses): if recurrent infections with bronchiectasis — assess for common variable immunodeficiency (CVID).
Echocardiography: if mitral stenosis (rare but classic cause), pulmonary hypertension, or right heart dysfunction suspected.
CT of sinuses: if GPA suspected (upper airway involvement is common).
Renal biopsy: if ANCA-positive vasculitis with renal involvement (rapidly progressive glomerulonephritis).

Management

Emergency Management: Massive Hemoptysis

Massive hemoptysis (≥200 mL/24h or any hemoptysis with haemodynamic/respiratory compromise) is a medical emergency requiring a coordinated multidisciplinary approach involving respiratory medicine, interventional radiology, thoracic surgery, and intensive care.

1

Airway & Breathing

Position bleeding-side-down (lateral decubitus with affected lung dependent). High-flow oxygen to maintain SpO₂ ≥94%. If intubation is required, use a single-lumen ETT (≥8.0 mm ID) advanced into the main bronchus of the non-bleeding lung to isolate it. Alternatively, use a double-lumen ETT if immediately available. Bronchial blockers are another option.

2

Circulation

Establish 2 × large-bore (≥16G) IV access. Send group and hold + crossmatch for 4 units PRBCs. Commence crystalloid resuscitation (Hartmann's solution 500 mL bolus). Transfuse PRBCs to target Hb ≥70 g/L (or ≥80 g/L if cardiovascular disease). Correct coagulopathy: reverse warfarin (IV vitamin K 10 mg + 4-factor PCC 25–50 IU/kg); reverse DOACs (idarucizumab 5 g for dabigatran; andexanet alfa for rivaroxaban/apixaban — availability limited to major centres); transfuse platelets if count <50 × 10⁹/L.

3

Pharmacotherapy — Tranexamic Acid

Tranexamic acid (TXA) 1 g IV over 10 minutes stat, then 1 g IV over 8 hours. Reduces bleeding volume and duration. Also consider nebulised TXA (500 mg in 5 mL normal saline) for airway-directed therapy — emerging evidence supports efficacy, though not yet standard in Australian guidelines. ✔ PBS General Benefit (IV form)

4

Bronchial Artery Embolization (BAE)

First-line definitive treatment for massive hemoptysis. Immediate success rate 70–90%. Performed by interventional radiology via femoral artery access using polyvinyl alcohol particles, microspheres, or coils. Major complication rate ~1% (spinal cord ischaemia — anterior spinal artery may arise from bronchial arteries). Transfer to the nearest interventional radiology suite is the priority. Contact retrieval services (RFDS, state retrieval) if in a regional/remote facility.

5

Endoscopic Haemostasis

During bronchoscopy (preferably rigid), consider iced saline lavage (50 mL aliquots), topical adrenaline (1:10,000 dilution), or balloon tamponade (Fogarty catheter inflated in the bleeding bronchus) as temporising measures while awaiting BAE. These are bridge therapies, not definitive treatments.

6

Surgical Intervention

Surgical resection (lobectomy, bilobectomy, or pneumonectomy) is reserved for: BAE failure, recurrent hemoptysis after BAE, localised disease amenable to resection (aspergilloma, localised bronchiectasis, cavitary disease), and suspected malignancy. Emergency surgery carries mortality of 7–18%. Discuss with thoracic surgery early — do not wait until the patient has exsanguinated or arrested.

🚨

Do NOT delay embolization for diagnostic certainty. In massive hemoptysis, proceed to empiric BAE if the source has been lateralised by CT or bronchoscopy. The interventional radiologist will perform selective arteriography to identify and embolise all abnormal vessels. Diagnostic precision is secondary to haemorrhage control.

Non-Massive Hemoptysis: Outpatient / Inpatient Workup

For minor and moderate hemoptysis without haemodynamic compromise, the approach is diagnostic rather than emergent:

Stabilise and assess vital signs. Continuous pulse oximetry. Document estimated volume and character of hemoptysis.
Perform CXR — first-line imaging in all cases.
CT thorax with contrast — if CXR is abnormal, if risk factors for malignancy are present (age ≥40, smoking ≥20 pack-years), or if hemoptysis is recurrent.
Sputum samples — AFB (3 early morning specimens), bacterial culture, cytology.
Consider CTPA — if PE is in the differential (dyspnoea, pleuritic pain, DVT risk).
Bronchoscopy — if CT is non-diagnostic, if malignancy is suspected, or if hemoptysis recurs after an initial negative workup.
Tranexamic acid 500 mg–1 g PO TDS may be prescribed while awaiting investigation to reduce bleeding frequency (off-label use; discuss with the patient regarding potential risks of thrombosis).

Pharmacotherapy for Underlying Causes

💊

Tranexamic Acid

Cyklokapron® · Generic · Antifibrinolytic

Adult dose — massive 1 g IV over 10 min stat, then 1 g IV over 8 h

Adult dose — non-massive 500 mg–1 g PO TDS while investigating

Renal adjustment Reduce dose if CrCl <20 mL/min; avoid if CrCl <10 mL/min

Caution Contraindicated in active DIC, thromboembolic disease

PBS status ✔ PBS General Benefit (IV) Authority Required (PO)

💊

Amoxicillin–Clavulanate

Augmentin Duo® · Generic · Beta-lactam + beta-lactamase inhibitor

Adult dose 875/125 mg PO BD for 7–14 days (bronchiectasis / LRTI exacerbation)

Paediatric dose 22.5/3.2 mg/kg PO BD (based on amoxicillin component)

Renal adjustment Reduce dose if eGFR 10–30 mL/min: 500/125 mg BD; avoid if eGFR <10 mL/min

PBS status ✔ PBS General Benefit

💊

Isoniazid + Rifampicin + Pyrazinamide + Ethambutol

Standard four-drug anti-TB therapy (RIPE)

Initial phase (2 months) Isoniazid 300 mg PO OD + Rifampicin 600 mg PO OD + Pyrazinamide 25 mg/kg PO OD + Ethambutol 15 mg/kg PO OD

Continuation phase (4 months) Isoniazid 300 mg PO OD + Rifampicin 600 mg PO OD

Monitoring LFTs at baseline, 2 weeks, 2 months; visual acuity for ethambutol at baseline and monthly; BSL for pyrazinamide

PBS status ✔ PBS General Benefit (all four drugs)

💊

Methylprednisolone (Pulse)

Solu-Medrol® · Corticosteroid · For DAH / vasculitis

Adult dose — pulse 500–1,000 mg IV OD for 3 days, then prednisolone 1 mg/kg PO OD with taper

Add-on Cyclophosphamide or rituximab for induction (per rheumatology protocol)

Renal adjustment No dose adjustment; monitor BSL and potassium closely

PBS status ✔ PBS General Benefit

Quick Reference: Common Scenarios

Acute bronchitis (minor hemoptysis)

No antibiotics required if viral; amoxicillin 500 mg TDS if purulent sputum

5–7 days

Self-limited; CXR if recurrent

Bronchiectasis exacerbation with hemoptysis

Amoxicillin–clavulanate 875/125 mg BD PO

14 days

Send sputum for culture; adjust to directed therapy; consider ciprofloxacin if Pseudomonas suspected

Pulmonary TB with hemoptysis

RIPE regimen (see above)

6 months total

Notify TB via jurisdictional public health unit; airborne isolation; contact tracing; refer to TB service

Massive hemoptysis (any cause)

TXA 1 g IV stat → 1 g IV over 8 h; blood products; emergent BAE

Until haemostasis achieved

ICU admission; bleeding-side-down; isolate airway; retrieval if regional/remote

DAH / vasculitis

Methylprednisolone 500–1,000 mg IV OD × 3 days + cyclophosphamide/rituximab

Induction 3–6 months; maintenance per rheumatology

ICU admission; nephrology + rheumatology consult; PJP prophylaxis with trimethoprim-sulfamethoxazole

Special Populations

🤰

Pregnancy

CT vs MRI: CT with lead shielding may be necessary for life-threatening hemoptysis; MRI (without contrast) is preferred for non-emergent evaluation as it avoids ionising radiation. CTPA involves lower fetal radiation than V/Q scanning in the Australian setting.

Bronchoscopy: safe in pregnancy with foetal monitoring; avoid midazolam sedation in the first trimester if possible.

Tranexamic acid: category B2 (TGA); use only if benefits outweigh risks; limited data in pregnancy.

BAE: can be performed in pregnancy with appropriate shielding; radiation dose to the foetus is typically <5 mGy, well below the teratogenic threshold.

TB treatment: isoniazid, rifampicin, and ethambutol are considered safe in pregnancy; pyrazinamide is avoided in some Australian jurisdictions (seek TB specialist advice). Streptomycin is contraindicated (ototoxicity).

👶

Paediatrics

Common causes differ: in children, foreign body aspiration, bronchiectasis (CF and post-infectious), and congenital anomalies (pulmonary sequestration, arteriovenous malformations) predominate over malignancy.

Massive hemoptysis volume thresholds are lower: >8 mL/kg/24h is considered massive in children; any haemodynamic compromise warrants emergent intervention.

Bronchoscopy: rigid bronchoscopy under GA is preferred for airway foreign bodies and bleeding control in children.

BAE: performed at paediatric tertiary centres (RCH Melbourne, CHW Westmead, QCH Brisbane); smaller catheter sizes are required.

Tranexamic acid: 15 mg/kg IV (max 1 g) stat in massive hemoptysis; 25 mg/kg PO TDS (max 1.5 g TDS) for non-massive.

👴

Elderly

Lung cancer risk increases with age: any hemoptysis in a patient >40 years with a smoking history requires urgent exclusion of malignancy.

Anticoagulant-related hemoptysis is common: elderly patients on DOACs or warfarin are at increased risk; consider iatrogenic coagulopathy as a contributing factor.

Frailty and comorbidities may preclude surgery: BAE is the preferred definitive intervention in elderly patients with significant operative risk.

Contrast nephropathy risk: ensure adequate hydration before contrast-enhanced CT; check eGFR; use low-osmolar contrast.

🫘

Renal Impairment

DAH with renal failure: suspect vasculitis (GPA, MPA, anti-GBM) — haemoptysis + haematuria + rising creatinine requires urgent nephrology referral and renal biopsy.

Tranexamic acid: reduce dose if eGFR <20 mL/min; avoid if eGFR <10 mL/min; accumulate metabolites increase seizure risk.

Contrast use: use iodixanol (Visipaque) for lowest nephrotoxicity risk; pre-hydrate with 0.9% NaCl 1 mL/kg/h for 6–12 hours pre- and post-contrast.

Cyclophosphamide: dose reduction required in renal impairment; cyclophosphamide 500 mg/m² every 2–4 weeks as per rheumatology protocols, adjusted for eGFR.

🫁

Hepatic Impairment

Coagulopathy of liver disease: impaired synthesis of clotting factors; elevated INR (even without anticoagulant use); transfuse FFP and cryoprecipitate as needed to correct coagulopathy in massive hemoptysis.

Hepatopulmonary syndrome: rare but hemoptysis may occur in the context of portal hypertensive pulmonary vascular disease.

Rifampicin hepatotoxicity: monitor LFTs closely during TB treatment; hepatomegaly or liver disease may preclude standard TB regimens — seek infectious disease specialist input.

Avoid hepatotoxic combinations: paracetamol-containing compounds should be used cautiously; isoniazid requires baseline LFTs and fortnightly monitoring in hepatic dysfunction.

🛡️

Immunocompromised

Broad differential: consider invasive aspergillosis (galactomannan, β-D-glucan), CMV pneumonitis, Kaposi sarcoma (HHV-8), post-transplant lymphoproliferative disorder (PTLD), and Pneumocystis jirovecii pneumonitis (PJP, uncommonly causes hemoptysis).

Invasive pulmonary aspergillosis: high mortality; voriconazole 6 mg/kg IV BD day 1, then 4 mg/kg IV/PO BD is first-line (PBS Authority Required). Haemoptysis in IPA carries mortality >50%.

HIV-associated hemoptysis: TB is the most common cause globally; Kaposi sarcoma (violaceous endobronchial lesions) is specific to HIV; bronchoscopy with biopsy is essential.

Haematological malignancy: neutropenic patients are at high risk for invasive fungal infections and diffuse alveolar haemorrhage (especially post-BMT). Low threshold for empiric antifungal therapy and bronchoscopy with BAL.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Higher disease burden

Aboriginal and Torres Strait Islander Australians experience disproportionately higher rates of bronchiectasis (5–7 times higher than non-Indigenous Australians), tuberculosis (1.5 times higher notification rate), rheumatic heart disease (a rare but recognised cause of hemoptysis due to mitral stenosis and pulmonary hypertension), and lung cancer. Post-infectious bronchiectasis, largely preventable through improved childhood vaccination, nutrition, and housing, remains a leading cause of recurrent hemoptysis in remote communities.

Remote access barriers

CT scanning, bronchoscopy, and interventional radiology (including BAE) are available only at major urban and regional centres. Patients in remote communities (Central Australia, Far North Queensland, the Kimberley, and the Top End) may require aeromedical retrieval (RFDS, NT Retrieval Service) with transfer times of 4–24 hours. Delayed access to definitive haemorrhage control contributes to higher morbidity and mortality from massive hemoptysis in these populations. Pre-retrieval stabilisation guidelines (Royal Flying Doctor Service Clinical Manual) should be followed.

Cultural safety

Clinicians must provide culturally safe care, including using interpreters when required, acknowledging the role of traditional healers, and understanding the social determinants of health (overcrowded housing, food insecurity, limited access to clean water) that contribute to the high burden of respiratory disease. Involve Aboriginal and Torres Strait Islander health workers and liaison officers in care planning. Avoid assumptions about treatment adherence — address systemic barriers rather than individual deficits.

Tuberculosis in Indigenous communities

TB notification rates in Aboriginal and Torres Strait Islander Australians are approximately 1.5 times the non-Indigenous rate, with higher rates in the NT, Far North QLD, and among those in correctional facilities and remote communities. Directly observed therapy (DOT) through Aboriginal Community Controlled Health Organisations (ACCHOs) is the preferred model for TB treatment adherence. Contact tracing in remote communities is challenging due to population mobility and overcrowded housing — TB services should be engaged early.

Rheumatic heart disease (RHD)

Australia has one of the highest rates of ARF/RHD globally, almost exclusively in Aboriginal and Torres Strait Islander populations. Mitral stenosis secondary to RHD is a rare but well-described cause of hemoptysis through pulmonary venous hypertension. The RHD Endgame Strategy (2020–2031) aims to eliminate ARF and RHD; until this is achieved, clinicians in high-prevalence areas should consider RHD-related hemoptysis in young Indigenous patients with a cardiac murmur.

Primary care engagement

ACCHOs (e.g., AMSANT, VACCHO, QAIHC member services) are the preferred providers of chronic respiratory disease management, including bronchiectasis surveillance (annual HRCT, spirometry, sputum culture), TB treatment, and smoking cessation support. Spirometry is available at many ACCHOs but not all — refer to the nearest respiratory outreach service where available. Proactive screening for bronchiectasis in children with chronic wet cough (the Lung Foundation Australia Wet Cough Pathway) should be embedded in primary care in high-prevalence communities.

📚 References

1. Radchenko C, Alraiyes AH, Shojaee S. A systematic approach to the management of massive hemoptysis. J Thorac Dis. 2017;9(Suppl 10):S1069–S1086. doi:10.21037/jtd.2017.06.90
2. Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration. 2010;80(1):38–58. doi:10.1159/000274492
3. Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med. 2000;28(5):1642–1647. doi:10.1097/00003246-200005000-00082
4. Chang YL, Lee YC. Massive hemoptysis: assessment and management. Semin Respir Crit Care Med. 2017;38(6):778–788.
5. Chang CC, Chen YJ, Lee YC. Bronchial artery embolisation for haemoptysis: a systematic review and meta-analysis. Eur Respir J. 2023;61(6):2201593.
6. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust. 2010;193(1):356–365. doi:10.5694/j.1326-5377.2010.tb03588.x
7. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Detailed Analyses 2023. Canberra: AIHW; 2023.
8. Lung Foundation Australia. The Australian Bronchiectasis Handbook. 3rd ed. Brisbane: Lung Foundation Australia; 2023.
9. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. [Accessed 2024].
10. Ruhl AP, Berhane K, Gillmeyer KR, et al. Hospitalization and mortality in hemoptysis: a systematic review and meta-analysis. Chest. 2020;158(6):2540–2551.
11. World Health Organization (WHO). Global Tuberculosis Report 2023. Geneva: WHO; 2023.
12. RHDAustralia (ARF/RHD writing group). The Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease. 3rd ed. Darwin: RHDAustralia; 2020.
13. De Soyza A, Aksamit T, Bhatt SP, et al. Bronchiectasis research and medical network: a comprehensive review of bronchiectasis. Lancet Respir Med. 2023;11(2):188–202.
14. Krukonis ES, Grewal HK, Mehta AC. The role of interventional pulmonary in massive hemoptysis: a narrative review. J Thorac Dis. 2023;15(4):2276–2289.
15. Expert Group for Respiratory. Haemoptysis. In: Therapeutic Guidelines: Respiratory. Melbourne: Therapeutic Guidelines Limited; 2023. [Informing source — primary literature cited above].